Medidata’s AI Achieves Top Rating in Everest Group’s 2026 Review

Event summary

  • Medidata received the highest 'Luminary' rating in Everest Group’s 2026 Innovation Watch for AI in clinical development.
  • The company achieved a 100% market adoption score, the only provider to do so among 18 global competitors.
  • Medidata’s AI supports 80% of FDA novel drug approvals in 2025, reducing enrollment times by up to 37% and data review cycles by up to 80%.
  • The recognition highlights Medidata’s integration of Generative, Agentic, and Advanced AI across its clinical trial platform.

The big picture

Medidata’s top rating underscores the growing importance of AI in accelerating drug development, a trend driven by the need for faster, more efficient clinical trials. As life sciences companies increasingly adopt AI, Medidata’s proprietary data assets and end-to-end platform position it as a key player in shaping the future of clinical research. The recognition also highlights the strategic value of Dassault Systèmes’ acquisition, integrating advanced AI capabilities into a broader digital innovation ecosystem.

What we're watching

AI Integration
How Medidata will sustain its lead in AI-driven clinical trial solutions amid increasing competition.
Regulatory Impact
Whether the FDA’s reliance on Medidata’s AI will influence future drug approval processes.
Market Expansion
The pace at which Medidata can expand its AI capabilities beyond clinical trials into other healthcare sectors.

Related topics

Clinical Trials